Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach.

Marsot A, Brevaut-Malaty V, Vialet R, Boulamery A, Bruguerolle B, Simon N.

Fundam Clin Pharmacol. 2014 Aug;28(4):465-71. doi: 10.1111/fcp.12042. Epub 2013 Jul 16.

PMID:
23855753
2.

Population pharmacokinetics of ertapenem in juvenile and old rats.

Boulamery A, Marsot A, Bruguerolle B, Simon N.

Fundam Clin Pharmacol. 2014 Apr;28(2):144-50. doi: 10.1111/fcp.12017. Epub 2013 May 5.

PMID:
23647486
3.

Population pharmacokinetic analysis during the first 2 years of life: an overview.

Marsot A, Boulamery A, Bruguerolle B, Simon N.

Clin Pharmacokinet. 2012 Dec;51(12):787-98. doi: 10.1007/s40262-012-0015-8. Review.

PMID:
23179579
4.

Vancomycin: Predictive Performance of a Population Pharmacokinetic Model and Optimal Dose in Neonates and Young Infants.

Marsot A, Vialet R, Boulamery A, Bruguerolle B, Simon N.

Clin Pharmacol Drug Dev. 2012 Oct;1(4):144-51. doi: 10.1177/2160763X12456843.

PMID:
27121456
5.

Vancomycin: a review of population pharmacokinetic analyses.

Marsot A, Boulamery A, Bruguerolle B, Simon N.

Clin Pharmacokinet. 2012 Jan 1;51(1):1-13. doi: 10.2165/11596390-000000000-00000. Review.

PMID:
22149255
6.

Penetration of ertapenem into muscle measured by in vivo microdialysis in mechanically ventilated patients.

Boyadjiev I, Boulamery A, Simon N, Martin C, Bruguerolle B, Leone M.

Antimicrob Agents Chemother. 2011 Jul;55(7):3573-5. doi: 10.1128/AAC.00180-11. Epub 2011 May 16.

7.

[Manufacturing waste of hemodialyzers decreases oxidative phosphorylation of mitochondria isolated from rats].

Brunet P, Simon N, Roubicek C, Papa K, Berland Y, Bruguerolle B.

Nephrol Ther. 2010 Dec;6(7):576-80. doi: 10.1016/j.nephro.2010.05.002. Epub 2010 Jul 3. French.

PMID:
20598955
8.

Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.

Boulamery A, Simon N, Vidal J, Bruguerolle B.

Chronobiol Int. 2010 Jan;27(2):251-64. doi: 10.3109/07420521003664213.

PMID:
20370468
9.

Effects of induced hyperthermia on pharmacokinetics of ropivacaine in rats.

Guilhaumou R, Boulamery A, Deluca B, Deturmeny E, Bruguerolle B.

Fundam Clin Pharmacol. 2010 Aug;24(4):463-8. doi: 10.1111/j.1472-8206.2009.00803.x. Epub 2009 Dec 11.

PMID:
20015226
10.

[Chronopharmacology and psychiatric treatment].

Bruguerolle B.

Encephale. 2009 Jan;35 Suppl 2:S58-62. doi: 10.1016/S0013-7006(09)75535-6. Review. French.

PMID:
19268172
11.

[Aspirin in decompression sickness].

Bessereau J, Coulange M, Genotelle N, Barthélémy A, Michelet P, Bruguerolle B, Annane D, Auffray JP.

Therapie. 2008 Nov-Dec;63(6):419-23. doi: 10.2515/therapie/2008067. Epub 2009 Feb 24. French.

PMID:
19236833
12.

[Biological rhythms and medications: a source of variability often neglected in pharmacology].

Bruguerolle B.

Ann Pharm Fr. 2008 Jun;66(3):185-90. doi: 10.1016/j.pharma.2008.05.005. Epub 2008 Jun 26. Review. French.

PMID:
18706347
13.

Effects of hyperthermia on pharmacokinetics of ertapenem in rats.

Boulamery A, Marouani H, Guilhaumou R, Rocher E, Simon N, Bruguerolle B.

Fundam Clin Pharmacol. 2008 Jun;22(3):285-9. doi: 10.1111/j.1472-8206.2008.00586.x.

PMID:
18485146
14.

Clinical chronopharmacology in the elderly.

Bruguerolle B.

Chronobiol Int. 2008 Feb;25(1):1-15. doi: 10.1080/07420520801909247. Review.

PMID:
18293146
15.

Independent-model diagnostics for a priori identification and interpretation of outliers from a full pharmacokinetic database: correspondence analysis, Mahalanobis distance and Andrews curves.

Semmar N, Urien S, Bruguerolle B, Simon N.

J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):159-83. doi: 10.1007/s10928-007-9082-0. Epub 2008 Feb 22.

PMID:
18293065
16.

Chronopharmacokinetics of imipenem in the rat.

Boulamery A, Kadra G, Simon N, Besnard T, Bruguerolle B.

Chronobiol Int. 2007;24(5):961-8.

PMID:
17994349
17.

Rhythmic pattern in pain and their chronotherapy.

Bruguerolle B, Labrecque G.

Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):883-95. Epub 2007 Jul 13. Review.

PMID:
17716777
18.

Biological rhythms: a neglected factor of variability in pharmacokinetic studies.

Bruguerolle B, Boulamery A, Simon N.

J Pharm Sci. 2008 Mar;97(3):1099-108. Review.

PMID:
17705158
19.

[Interactions of melatonin with the central nervous system].

Bruguerolle B.

Encephale. 2006 Oct;32(5 Pt 2):S818-25. Review. French. No abstract available.

PMID:
17119478
20.

Effects of a seven-day continuous infusion of ropivacaine on circadian rhythms in the rat.

Velly AB, Simon N, Bedidjian S, Bruguerolle B.

Chronobiol Int. 2006;23(3):683-93.

PMID:
16865808
21.

Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients.

Simon N, Dussol B, Sampol E, Purgus R, Brunet P, Lacarelle B, Berland Y, Bruguerolle B, Urien S.

Clin Pharmacokinet. 2006;45(5):493-501.

PMID:
16640454
22.

Cluster analysis: an alternative method for covariate selection in population pharmacokinetic modeling.

Semmar N, Bruguerolle B, Boullu-Ciocca S, Simon N.

J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):333-58.

PMID:
16307207
23.

Effects of three-hour restricted food access during the light period on circadian rhythms of temperature, locomotor activity, and heart rate in rats.

Boulamery-Velly A, Simon N, Vidal J, Mouchet J, Bruguerolle B.

Chronobiol Int. 2005;22(3):489-98.

PMID:
16076649
24.

Effect of lithium on norepinephrine metabolic pathways.

Sastre E, Nicolay A, Bruguerolle B, Portugal H.

Life Sci. 2005 Jul 1;77(7):758-67. Epub 2005 Mar 17.

PMID:
15936350
25.

[Involvement of a public pharmacology laboratory in pharmacokinetic studies].

Simon N, Boulamery A, Bruguerolle B.

Therapie. 2004 Mar-Apr;59(2):169-71. French.

PMID:
15359607
26.

The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease.

Simon N, Gantcheva R, Bruguerolle B, Viallet F.

Parkinsonism Relat Disord. 2004 Mar;10(3):137-42.

PMID:
15036167
28.

High plasma ropivacaine concentrations after fascia iliaca compartment block in children.

Paut O, Schreiber E, Lacroix F, Meyrieux V, Simon N, Lavrut T, Camboulives J, Bruguerolle B.

Br J Anaesth. 2004 Mar;92(3):416-8. Epub 2004 Jan 22.

29.

Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia.

Leone M, Albanèse J, Sampol-Manos E, Simon N, Lacarelle B, Bruguerolle B, Martin C.

Antimicrob Agents Chemother. 2004 Feb;48(2):638-40.

30.

Chronobiology and anesthesia.

Chassard D, Bruguerolle B.

Anesthesiology. 2004 Feb;100(2):413-27. Review. No abstract available.

PMID:
14739819
31.

Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia.

Simon N, Sampol E, Albanese J, Martin C, Arvis P, Urien S, Lacarelle B, Bruguerolle B.

Clin Pharmacol Ther. 2003 Oct;74(4):353-63.

PMID:
14534522
32.

Circadian rhythms of oxidative phosphorylation: effects of rotenone and melatonin on isolated rat brain mitochondria.

Simon N, Papa K, Vidal J, Boulamery A, Bruguerolle B.

Chronobiol Int. 2003 May;20(3):451-61.

PMID:
12868540
33.

Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria.

Simon N, Morin C, Urien S, Tillement JP, Bruguerolle B.

Br J Pharmacol. 2003 Jan;138(2):369-76.

34.

Air-stepping in neonatal rats: A comparison of L-dopa injection and olfactory stimulation.

Jamon M, Maloum I, Riviere G, Bruguerolle B.

Behav Neurosci. 2002 Dec;116(6):1014-21.

PMID:
12492300
35.

Lack of daily rhythms major modifications despite continuous infusion of melatonin in the rat.

Simon N, Vidal J, Mouchet J, Bruguerolle B.

J Vet Pharmacol Ther. 2002 Aug;25(4):285-8.

PMID:
12213117
36.

Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function.

Bruguerolle B, Simon N.

Clin Neuropharmacol. 2002 Jul-Aug;25(4):194-201. Review.

PMID:
12151906
37.

Chronotherapy and compliance: impairment or improvement?

Bruguerolle B, Simon N.

Chronobiol Int. 2002 Mar;19(2):498-502. No abstract available.

PMID:
12025938
38.

Time-of-day dependent pharmacodynamic and pharmacokinetic profiles of caffeine in rats.

Pelissier-Alicot AL, Schreiber-Deturmeny E, Simon N, Gantenbein M, Bruguerolle B.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Apr;365(4):318-25. Epub 2002 Feb 14.

PMID:
11919657
39.

[Effects of trimetazidine on altered functions of rat kidney induced by cyclosporine].

Simon N, Morin C, Bruguerolle B, Tillement JP.

Therapie. 2001 Sep-Oct;56(5):583-7. French.

PMID:
11806297
40.

A double blind parallel group placebo controlled comparison of sedative and mnesic effects of etifoxine and lorazepam in healthy subjects [corrected].

Micallef J, Soubrouillard C, Guet F, Le Guern ME, Alquier C, Bruguerolle B, Blin O.

Fundam Clin Pharmacol. 2001 Jun;15(3):209-16. Erratum in: Fundam Clin Pharmacol. 2003 Oct;17(5):643.

PMID:
11468032
41.

Continuous fascia iliaca compartment block in children: a prospective evaluation of plasma bupivacaine concentrations, pain scores, and side effects.

Paut O, Sallabery M, Schreiber-Deturmeny E, Rémond C, Bruguerolle B, Camboulives J.

Anesth Analg. 2001 May;92(5):1159-63.

PMID:
11323339
42.

Pharmacokinetic and pharmacodynamic analysis of sedative and amnesic effects of lorazepam in healthy volunteers.

Blin O, Simon N, Jouve E, Habib M, Gayraud D, Durand A, Bruguerolle B, Pisano P.

Clin Neuropharmacol. 2001 Mar-Apr;24(2):71-81.

PMID:
11307041
43.
44.

Effects of a seven-day continuous infusion of L-DOPA on daily rhythms in the rat.

Simon N, Mouchet J, Bruguerolle B.

Eur J Pharmacol. 2000 Jul 28;401(1):79-83.

PMID:
10915840
45.

Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit.

Albanèse J, Léone M, Bruguerolle B, Ayem ML, Lacarelle B, Martin C.

Antimicrob Agents Chemother. 2000 May;44(5):1356-8.

46.

Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A.

Gantenbein M, Attolini L, Bruguerolle B, Villard PH, Puyoou F, Durand A, Lacarelle B, Hardwigsen J, Le-Treut YP.

Drug Metab Dispos. 2000 Apr;28(4):383-5.

PMID:
10725304
48.

Pharmacokinetic-pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers.

Blin O, Jacquet A, Callamand S, Jouve E, Habib M, Gayraud D, Durand A, Bruguerolle B, Pisano P.

Br J Clin Pharmacol. 1999 Oct;48(4):510-2.

49.

Metabolic and hemodynamic changes during recovery and tracheal extubation in neurosurgical patients: immediate versus delayed recovery.

Bruder N, Stordeur JM, Ravussin P, Valli M, Dufour H, Bruguerolle B, Francois G.

Anesth Analg. 1999 Sep;89(3):674-8.

PMID:
10475304
50.

Caffeine-induced modifications of heart rate, temperature, and motor activity circadian rhythms in rats.

Pelissier AL, Gantenbein M, Bruguerolle B.

Physiol Behav. 1999 Aug 1;67(1):81-8.

PMID:
10463632

Supplemental Content

Loading ...
Support Center